vs
Side-by-side financial comparison of COMMERCE BANCSHARES INC (CBSH) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $475.7M, roughly 1.6× COMMERCE BANCSHARES INC). COMMERCE BANCSHARES INC runs the higher net margin — 29.8% vs 13.0%, a 16.8% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 11.1%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 7.1%).
Commerce Bancshares, Inc. is a regional bank holding company headquartered in Missouri, with principal offices in Kansas City and St. Louis. It is the corporate parent of Commerce Bank, which offers a diversified line of financial services, including business and personal banking, wealth management and investments through its affiliated companies.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
CBSH vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $475.7M | $783.7M |
| Net Profit | $141.6M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 29.8% | 13.0% |
| Revenue YoY | 11.1% | 31.2% |
| Net Profit YoY | 10.5% | 0.9% |
| EPS (diluted) | $0.96 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $475.7M | — | ||
| Q4 25 | $449.4M | $783.7M | ||
| Q3 25 | $441.0M | $706.3M | ||
| Q2 25 | $445.8M | $649.1M | ||
| Q1 25 | $428.1M | $569.0M | ||
| Q4 24 | $422.1M | $597.5M | ||
| Q3 24 | $421.4M | $543.9M | ||
| Q2 24 | $414.5M | $488.5M |
| Q1 26 | $141.6M | — | ||
| Q4 25 | $140.7M | $101.6M | ||
| Q3 25 | $141.5M | $87.6M | ||
| Q2 25 | $152.5M | $22.5M | ||
| Q1 25 | $131.6M | $35.4M | ||
| Q4 24 | $136.1M | $100.7M | ||
| Q3 24 | $138.0M | $77.5M | ||
| Q2 24 | $139.6M | $188.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | 40.8% | 18.7% | ||
| Q3 25 | 41.9% | 16.7% | ||
| Q2 25 | 44.0% | 18.7% | ||
| Q1 25 | 39.2% | 15.6% | ||
| Q4 24 | 41.2% | 18.3% | ||
| Q3 24 | 42.4% | 16.2% | ||
| Q2 24 | 43.4% | 11.2% |
| Q1 26 | 29.8% | — | ||
| Q4 25 | 31.3% | 13.0% | ||
| Q3 25 | 32.1% | 12.4% | ||
| Q2 25 | 34.2% | 3.5% | ||
| Q1 25 | 30.7% | 6.2% | ||
| Q4 24 | 32.2% | 16.9% | ||
| Q3 24 | 32.8% | 14.2% | ||
| Q2 24 | 33.7% | 38.6% |
| Q1 26 | $0.96 | — | ||
| Q4 25 | $0.86 | $1.42 | ||
| Q3 25 | $1.06 | $1.24 | ||
| Q2 25 | $1.14 | $0.32 | ||
| Q1 25 | $0.98 | $0.50 | ||
| Q4 24 | $0.83 | $1.38 | ||
| Q3 24 | $1.01 | $1.08 | ||
| Q2 24 | $1.03 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $4.3B | $1.5B |
| Total Assets | $35.7B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $3.8B | $1.5B | ||
| Q3 25 | $3.8B | $1.4B | ||
| Q2 25 | $3.6B | $1.5B | ||
| Q1 25 | $3.5B | $1.3B | ||
| Q4 24 | $3.3B | $1.2B | ||
| Q3 24 | $3.4B | $1.1B | ||
| Q2 24 | $3.1B | $998.4M |
| Q1 26 | $35.7B | — | ||
| Q4 25 | $32.9B | $3.2B | ||
| Q3 25 | $32.3B | $3.0B | ||
| Q2 25 | $32.3B | $3.5B | ||
| Q1 25 | $32.4B | $3.5B | ||
| Q4 24 | $32.0B | $3.1B | ||
| Q3 24 | $31.5B | $3.0B | ||
| Q2 24 | $30.6B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $645.1M | $183.3M | ||
| Q3 25 | $129.0M | $125.7M | ||
| Q2 25 | $111.2M | $196.5M | ||
| Q1 25 | $138.6M | $63.8M | ||
| Q4 24 | $577.9M | $147.7M | ||
| Q3 24 | $431.7M | $98.5M | ||
| Q2 24 | $147.4M | $96.5M |
| Q1 26 | — | — | ||
| Q4 25 | $592.4M | $48.2M | ||
| Q3 25 | $113.3M | $100.1M | ||
| Q2 25 | $100.5M | $177.9M | ||
| Q1 25 | $126.0M | $51.5M | ||
| Q4 24 | $531.7M | $94.1M | ||
| Q3 24 | $419.1M | $71.8M | ||
| Q2 24 | $138.9M | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | 131.8% | 6.2% | ||
| Q3 25 | 25.7% | 14.2% | ||
| Q2 25 | 22.5% | 27.4% | ||
| Q1 25 | 29.4% | 9.1% | ||
| Q4 24 | 126.0% | 15.7% | ||
| Q3 24 | 99.5% | 13.2% | ||
| Q2 24 | 33.5% | 15.1% |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | 17.2% | ||
| Q3 25 | 3.6% | 3.6% | ||
| Q2 25 | 2.4% | 2.9% | ||
| Q1 25 | 2.9% | 2.2% | ||
| Q4 24 | 10.9% | 9.0% | ||
| Q3 24 | 3.0% | 4.9% | ||
| Q2 24 | 2.1% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.59× | 1.80× | ||
| Q3 25 | 0.91× | 1.43× | ||
| Q2 25 | 0.73× | 8.73× | ||
| Q1 25 | 1.05× | 1.80× | ||
| Q4 24 | 4.25× | 1.47× | ||
| Q3 24 | 3.13× | 1.27× | ||
| Q2 24 | 1.06× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBSH
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
